| HOME >> MEDICINE >> TECHNOLOGY |
——2,000—Settlements and loss contingencies, net
——45,000190,560Restructuring costs
—26,986—26,986Total operating expenses
60,38381,219179,442329,434Operating income (loss)
82,77117,80761,558(120,755)Interest income
140382276805Interest expense
(3,069)(150)(6,163)(301)Income (loss) from continuing operations beforeprovision (benefit) for income taxes
79,84218,03955,671(120,251)Provision (benefit) for income taxes
28,5378,85933,062(20,587)Income (loss) from continuing operations
51,3059,18022,609(99,664)Discontinued operations:Provision for income taxes
2812755253Loss from discontinued operations
(28)(127)(55)(253)Net income (loss)
$
51,277$
9,053$
22,554$
(99,917)Basic earnings (loss) per share of common stock:Income (loss) from continuing operations
$
1.41$
0.26$
0.62$
(2.79)Loss from discontinued operations
—(0.01)—(0.01)Net income (loss)
$
1.41$
0.25$
0.62$
(2.80)Diluted earnings (loss) per share of common stock:Income (loss) from continuing operations
$
1.38$
0.25$
0.61$
(2.79)Loss from discontinued operations
———(0.01)Net income (loss)
$
1.38$
0.25$
0.61$
(2.80)Weighted average number of common sharesoutstanding:Basic
36,47835,98336,39235,742Diluted
37,19436,70837,12235,742
Reconciliation Between Reported (GAAP); Adjusted Income (Loss) from Continuing Operations and "Cash EPS"
(In Thousands, Except Per Share Data)
(Unaudited)
| SOURCE Par Pharmaceutical Companies, Inc. Copyright©2012 PR Newswire. All rights reserved |